Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein.
Journal
Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686
Informations de publication
Date de publication:
11 Jan 2024
11 Jan 2024
Historique:
received:
30
04
2023
accepted:
26
10
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
Chronic orofacial pain (COP) is relieved by duloxetine (DLX) and frequently causes depressive symptoms. The aim of this study was to confirm effects of DLX on pain and depressive symptoms, and to associate with their effectiveness in platelet serotonin transporter (SERT) expression, which is a target molecule of DLX and plasma serotonin concentration in COP patients with depressive symptoms. We assessed for the severity of pain and depressive symptoms using the Visual Analog Scale (VAS) and 17-item Hamilton Depression Rating Scale (HDRS), respectively. Chronic orofacial pain patients were classified into 2 groups based on their HDRS before DLX-treatment: COP patients with (COP-D) and without (COP-ND) depressive symptoms. We found that the VAS and HDRS scores of both groups were significantly decreased after DLX treatment compared with those before DLX treatment. Upregulation of total SERT and downregulation of ubiquitinated SERT were observed before DLX treatment in both groups compared with healthy controls. After DLX treatment, there were no differences in total SERT of both groups and in ubiquitinated SERT of COP-D patients compared with healthy controls; whereas, ubiquitinated SERT of COP-ND patients remained downregulated. There were positive correlations between changes of serotonin concentrations and of VAS or HDRS scores in only COP-D patients. Our findings indicate that DLX improves not only pain but also comorbid depressive symptoms of COP-D patients. Duloxetine also reduces platelet SERT through upregulation of ubiquitinated SERT. As the result, decrease of plasma serotonin concentrations may be related to the efficacy of DLX in relieving pain and depression in COP patients.
Identifiants
pubmed: 38227563
doi: 10.1097/j.pain.0000000000003124
pii: 00006396-990000000-00499
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 21H04815
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 21H04815
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 17K10325
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 21K06719
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 19K17108
Organisme : Japan Agency for Medical Research and Development
ID : JP21dk0307103,
Organisme : Japan Agency for Medical Research and Development
ID : JP21dk0307087
Organisme : Japan Agency for Medical Research and Development
ID : P21wm0425007
Organisme : Japan Agency for Medical Research and Development
ID : JP21dm0207075
Organisme : Japan Agency for Medical Research and Development
ID : JP21dm0207075
Organisme : Japan Agency for Medical Research and Development
ID : JP21ek0109498
Organisme : Adaptable and Seamless Technology Transfer Program through Target-Driven R and D
ID : AS251Z03018
Informations de copyright
Copyright © 2024 International Association for the Study of Pain.
Références
Albuquerque RJC, de Leeuw R, Carlson CR, Okeson JP, Miller CS, Andersen AH. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: an fMRI study. PAIN 2006;122:223–34.
Alvarez JC, Gluck N, Fallet A, Grégoire A, Chevalier JF, Advenier C, Spreux-Varoquaux O. Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response? Psychopharmacology (Berl) 1999;143:97–101.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Publishing, Inc, 2013. Available at: https://doi.org/10.1176/appi.books.9780890425596. Accessed October 30, 2022.
Andre K, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Mononen N, Lehtimäki T, Haraldsson S, Koivisto PA, Leinonen E. SERT and NET polymorphisms, temperament and antidepressant response. Nord J Psychiatry 2015;69:531–8.
Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433–45.
Baudry A, Pietri M, Launay JM, Kellermann O, Schneider B. Multifaceted regulations of the serotonin transporter: impact on antidepressant response. Front Neurosci 2019;13:91.
Blardi P, de Lalla A, Urso R, Auteri A, Dell'Erba A, Bossini L, Castrogiovanni P. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J Clin Psychopharmacol 2005;25:262–6.
Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 2007;102:206–15.
Cai L, He Q, Lu Y, Hu Y, Chen W, Wei L, Hu Y. Comorbidity of pain and depression in a lumbar disc herniation model: biochemical alterations and the effects of fluoxetine. Front Neurol 2019;10:1022.
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386–9.
Clark GT. Persistent orodental pain, atypical odontalgia, and phantom tooth pain: when are they neuropathic disorders? J Calif Dent Assoc 2006;34:599–609.
Ding Y, Dai J. Advance in stress for depressive disorder. Adv Exp Med Biol 2019;1180:147–78.
Ducasse D, Courtet P, Olie E. Burning mouth syndrome: current clinical, physiopathologic, and therapeutic data. Reg Anesth Pain Med 2013;38:380–90.
Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P, Plomin R, Craig IW. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004;9:908–15.
Ernberg M, Hedenberg-Magnusson B, Alstergren P, Lundeberg T, Kopp S. Pain, allodynia, and serum serotonin level in orofacial pain of muscular origin. J Orofac Pain 1999;13:56–62.
Ernberg M, Voog U, Alstergren P, Lundeberg T, Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain 2000;14:37–46.
Forssell H, Jääskeläinen S, List T, Svensson P, Baad-Hansen L. An update on pathophysiological mechanisms related to idiopathic oro-facial pain conditions with implications for management. J Oral Rehabil 2015;42:300–22.
Fukuo Y, Kishi T, Kushima I, Yoshimura R, Okochi T, Kitajima T, Matsunaga S, Kawashima K, Umene-Nakano W, Naitoh H, Inada T, Nakamura J, Ozaki N, Iwata N. Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population. J Affect Disord 2011;133:150–7.
Furness JB, Costa M. Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the Guinea-pig small intestine. Neuroscience 1982;7:341–9.
Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010;67:133–8.
Ghurye S, McMillan R. Orofacial pain - an update on diagnosis and management. Br Dent J 2017;223:639–47.
Gormanns P, Mueller NS, Ditzen C, Wolf S, Holsboer F, Turck CW. Phenome-transcriptome correlation unravels anxiety and depression related pathways. J Psychiatr Res 2011;45:973–9.
Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression—a central role for the serotonin transporter? Pharmacol Ther 2015;147:1–11.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
Hasegawa S, Miyake Y, Yoshimi A, Mouri A, Hida H, Yamada K, Ozaki N, Nabeshima T, Noda Y. Dysfunction of serotonergic and dopaminergic neuronal systems in the antidepressant-resistant impairment of social behaviors induced by social defeat stress exposure as juveniles. Int J Neuropsychopharmacol 2018;21:837–46.
Hayes MH, Patterson DG. Experimental development of the graphic rating method. Psychol Bull 1921;18:98–9.
Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia 2013;33:629–808.
Holck A, Wolkowitz OM, Mellon SH, Reus VI, Nelson JC, Westrin Å, Lindqvist D. Plasma serotonin levels are associated with antidepressant response to SSRIs. J Affect Disord 2019;250:65–70.
Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576–84.
Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011;68:444–54.
Kekuda R, Leibach FH, Furesz TC, Smith CH, Ganapathy V. Polarized distribution of interleukin-1 receptors and their role in regulation of serotonin transporter in placenta. J Pharmacol Exp Ther 2000;292:1032–41.
Kesic M, Tvrdeic A, Kolaric D, Stojkovic R, Cicin-Sain L. Serotonergic modulation of pain and analgesic responses: a study in rats with constitutionally altered serotonin transporters. Eur J Pain 2015;19:508–15.
Kim YD, Lee JH, Shim JH. Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: a case report. J Int Med Res 2014;42:879–83.
Kishore J, Shaikh F, Mirza S, Raffat MA, Ikram S, Akram Z. Cytokine levels and their role in the etiopathogenesis of burning mouth syndrome: a systematic review. Cephalalgia 2019;39:1586–94.
Kobayashi Y, Nagashima W, Tokura T, Yoshida K, Umemura E, Miyauchi T, Arao M, Ito M, Kimura H, Kurita K, Ozaki N. Duloxetine plasma concentrations and its effectiveness in the treatment of nonorganic chronic pain in the orofacial region. Clin Neuropharmacol 2017;40:163–8.
Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A, Sapelli P. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. PAIN 2005;115:332–7.
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527–31.
Lingjaerde O. Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 1990;66(suppl 3):61–8.
Malynn S, Campos-Torres A, Moynagh P, Haase J. The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 2013;38:694–704.
McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev 2016;11:CD002779.
Melis M, Secci S. Diagnosis and treatment of atypical odontalgia: a review of the literature and two case reports. J Contemp Dent Pract 2007;8:81–9.
Mercado CP, Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv 2010;10:231–41.
Mignogna MD, Adamo D, Schiavone V, Ravel MG, Fortuna G. Burning mouth syndrome responsive to duloxetine: a case report. Pain Med 2011;12:466–9.
Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355–474.
Miyauchi T, Tokura T, Kimura H, Ito M, Umemura E, Sato Boku A, Nagashima W, Tonoike T, Yamamoto Y, Saito K, Kurita K, Ozaki N. Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region. Hum Psychopharmacol 2019;34:e2698.
Moghadam-Kia S, Fazel N. A diagnostic and therapeutic approach to primary burning mouth syndrome. Clin Dermatol 2017;35:453–60.
Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998;349:317–24.
Mössner R, Daniel S, Schmitt A, Albert D, Lesch KP. Modulation of serotonin transporter function by interleukin-4. Life Sci 2001;68:873–80.
Mössner R, Heils A, Stöber G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998;33:251–4.
Mouri A, Sasaki A, Watanabe K, Sogawa C, Kitayama S, Mamiya T, Miyamoto Y, Yamada K, Noda Y, Nabeshima T. MAGE-D1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation. J Neurosci 2012;32:4562–80.
Nagashima W, Kimura H, Ito M, Tokura T, Arao M, Aleksic B, Yoshida K, Kurita K, Ozaki N. Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain. Clin Neuropharmacol 2012;35:273–7.
Nakajima K, Obata H, Iriuchijima N, Saito S. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. PAIN 2012;153:990–7.
Nakamura M, Yoshimi A, Mouri A, Tokura T, Kimura H, Kishi S, Miyauchi T, Iwamoto K, Ito M, Sato-Boku A, Ozaki N, Nabeshima T, Noda Y. Duloxetine attenuates pain in association with downregulation of platelet serotonin transporter in patients with burning mouth syndrome and atypical odontalgia. Hum Psychopharmacol 2022;37:e2818.
Noda Y, Mamiya T, Furukawa H, Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 1997;324:135–40.
Nosratzehi T. Burning mouth syndrome: a review of therapeutic approach. J Complement Integr Med 2021;19:83–90.
Okubo M. Burning mouth syndrome: recent research trends and management recommendations. Jpn J Orofacial Pain 2010;3:33–42.
Palit S, Sheaff RJ, France CR, McGlone ST, Potter WT, Harkness AR, McNulty JL, Bartley EJ, Hoffmann R, Monda JK, Rhudy JL. Serotonin transporter gene (5-HTTLPR) polymorphisms are associated with emotional modulation of pain but not emotional modulation of spinal nociception. Biol Psychol 2011;86:360–9.
Popa D, Cerdan J, Repérant C, Guiard BP, Guilloux JP, David DJ, Gardier AM. A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. Eur J Pharmacol 2010;628:83–90.
Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, Ganapathy V. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 1995;216:560–7.
Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanás T. A systematic review of efficacy, safety, and tolerability of duloxetine. Front Psychiatry 2020;11:554899.
Saffarpour S, Nasirinezhad F. The CA1 hippocampal serotonin alterations involved in anxiety-like behavior induced by sciatic nerve injury in rats. Scand J Pain 2021;21:135–44.
Sbrini G, Brivio P, Bosch K, Homberg JR, Calabrese F. Enrichment environment positively influences depression- and anxiety-like behavior in serotonin transporter knockout rats through the modulation of neuroplasticity, spine, and GABAergic markers. Genes (Basel) 2020;11:1248.
Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003;14:275–91.
Sekine N, Okada-Ogawa A, Asano S, Takanezawa D, Nishihara C, Tanabe N, Imamura Y. Analgesic effect of gum chewing in patients with burning mouth syndrome. J Oral Sci 2020;62:387–92.
Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL. In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration. Synapse 2000;38:460–70.
Thor KB, Kirby M, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 2007;61:1349–55.
Treister R, Pud D, Ebstein RP, Laiba E, Raz Y, Gershon E, Haddad M, Eisenberg E. Association between polymorphisms in serotonin and dopamine-related genes and endogenous pain modulation. J Pain 2011;12:875–83.
Tsao CW, Lin YS, Cheng JT, Lin CF, Wu HT, Wu SR, Tsai WH. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 2008;22:753–60.
Tu TTH, Miura A, Shinohara Y, Mikuzuki L, Kawasaki K, Sugawara S, Suga T, Watanabe T, Watanabe M, Umezaki Y, Yoshikawa T, Motomura H, Takenoshita M, Toyofuku A. Evaluating Burning mouth syndrome as a comorbidity of atypical odontalgia: the impact on pain experiences. Pain Pract 2018;18:580–6.
Woda A, Pionchon P. A unified concept of idiopathic orofacial pain: clinical features. J Orofac Pain 1999;13:172–84; discussion 185–95.
Yamazaki Y, Hata H, Kitamori S, Onodera M, Kitagawa Y. An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e6–11.
Yubero-Lahoz S, Robledo P, Farré M, de laTorre R. Platelet SERT as a peripheral biomarker of serotonergic neurotransmission in the central nervous system. Curr Med Chem 2013;20:1382–96.
Zakrzewska J, Buchanan JA. Burning mouth syndrome. BMJ Clin Evid 2016;2016:1301.
Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994;643:40–9.
Zhuang X, Xu H, Fang Z, Xu C, Xue C, Hong X. Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients. Eur J Pharmacol 2018;834:213–20.
Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord 2013;150:384–8.